In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…